DK3675865T3 - Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød - Google Patents

Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød Download PDF

Info

Publication number
DK3675865T3
DK3675865T3 DK18849724.2T DK18849724T DK3675865T3 DK 3675865 T3 DK3675865 T3 DK 3675865T3 DK 18849724 T DK18849724 T DK 18849724T DK 3675865 T3 DK3675865 T3 DK 3675865T3
Authority
DK
Denmark
Prior art keywords
compounds
preventing
cell death
crystalline forms
hair cell
Prior art date
Application number
DK18849724.2T
Other languages
English (en)
Inventor
Graham Johnson
Edwin Aret
Alexei Tchesnokov
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of DK3675865T3 publication Critical patent/DK3675865T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK18849724.2T 2017-09-01 2018-08-31 Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød DK3675865T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553568P 2017-09-01 2017-09-01
PCT/US2018/049113 WO2019046731A1 (en) 2017-09-01 2018-08-31 CRYSTALLINE FORMS OF COMPOUNDS FOR PREVENTING OR TREATING DEATH OF SENSORY CILIC CELLS

Publications (1)

Publication Number Publication Date
DK3675865T3 true DK3675865T3 (da) 2025-05-26

Family

ID=65526112

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18849724.2T DK3675865T3 (da) 2017-09-01 2018-08-31 Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød

Country Status (10)

Country Link
US (1) US11779573B2 (da)
EP (1) EP3675865B1 (da)
JP (1) JP7397487B2 (da)
KR (1) KR20200086257A (da)
CN (1) CN111315385A (da)
AU (1) AU2018325267B2 (da)
CA (1) CA3072347C (da)
DK (1) DK3675865T3 (da)
ES (1) ES3033299T3 (da)
WO (1) WO2019046731A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3675865B1 (en) 2017-09-01 2025-04-02 University of Washington Crystalline forms of compounds for preventing or treating sensory hair cell death

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
WO2014052914A1 (en) * 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2016127123A2 (en) 2015-02-06 2016-08-11 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
EP3675865B1 (en) 2017-09-01 2025-04-02 University of Washington Crystalline forms of compounds for preventing or treating sensory hair cell death

Also Published As

Publication number Publication date
KR20200086257A (ko) 2020-07-16
EP3675865B1 (en) 2025-04-02
US11779573B2 (en) 2023-10-10
US20200345705A1 (en) 2020-11-05
EP3675865A4 (en) 2021-06-02
CN111315385A (zh) 2020-06-19
AU2018325267B2 (en) 2023-03-30
JP2020532522A (ja) 2020-11-12
ES3033299T3 (en) 2025-08-01
AU2018325267A1 (en) 2020-02-27
CA3072347A1 (en) 2019-03-07
EP3675865A1 (en) 2020-07-08
WO2019046731A1 (en) 2019-03-07
JP7397487B2 (ja) 2023-12-13
CA3072347C (en) 2024-03-26

Similar Documents

Publication Publication Date Title
EP3773896A4 (en) Controlled release of radionuclides
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
PL3314343T3 (pl) Osobiste drony sensoryczne
EP3457850C0 (en) SYNERGISTIC COMBINATION OF BIOCIDES
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
PL3265053T3 (pl) Sposoby leczenia skóry
DK3234145T3 (da) Fremgangsmåde til kontrollered aktivering eller eliminering af terapeutiske celler
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
EP3307739A4 (en) NRF2-REGULATORS
HUE041412T2 (hu) Integratív gomba oldatok méhek védelmére
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
EP3380062A4 (en) Compositions for treating the hair
DK3261726T3 (da) Sammensætning til behandling af acne
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
PT3353168T (pt) Compostos e métodos para inibir jak
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
DK3307299T3 (da) Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer
EP3381018A4 (en) TRIGGER THE REGIONS
PL3400269T3 (pl) Zastosowanie 4-bora-3a,4a-diaza-s-indacenów do zabezpieczania
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3220952T3 (da) Fremgangsmåde til behandling eller forebyggelse af slagtilfælde